Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor

Executive Summary

In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.


Related Content

Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
Triple Immunotherapy Combos Enter The Ovarian Cancer Fight
Deal Watch: Best Value For Smaller Firms Lies In The Back-End
Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss
Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets
Incyte Tumbles On More Jakafi Trial Terminations
Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts